Open Nav

Please submit your session questions in advance at


  • William Annett, OncoCyte

OncoCyte is focused on the development and commercialization of novel, non-invasive blood (“liquid biopsy”) diagnostic tests for the early detection of cancer. Early detection of cancer can improve health outcomes, reduce the cost of care, and improve patients’ quality of life. Liquid biopsy diagnostic tests like those OncoCyte is developing may reduce the need for costlier and riskier diagnostic procedures such as invasive biopsy procedures.

OncoCyte’s is focusing its efforts on developing DetermaVu™ as a non-invasive confirmatory diagnostic test for lung cancer. DetermaVu™ is being developed using proprietary sets of genetic and protein molecular markers to detect the presence of lung cancer.

  • Date:Monday, February 11
  • Time:10:30 AM - 10:45 AM
  • Room:Hudson/Empire
  • Location:7th Floor
  • Session Type:Company Presentation
  • Please submit your session questions in advance:

    Click here.

  • Submission ID:23272
  • Company Presentation - Presentation Type:Publicly Traded Company
  • Goal for Presentation:Investor awareness
  • Company Website:
  • Company HQ City:Alameda
  • Company HQ State:California
  • Company HQ Country:United States
  • Ticker:OCX
  • Exchange:NYSE American
  • CEO/Top Company Official:William Annett
  • Main Therapeutic Focus:Diagnostics
  • Lead Product in Development:Liquid biopsy diagnostic for lung cancer
  • Development Phase of Primary Product:Other/Not Applicable
William Annett